Pfizer: Annual COVID shots preferable to frequent boosters
January 24, 2022Sales and Marketing
Pfizer CEO Albert Bourla has commented that an annual COVID-19 vaccine would be preferable to more frequent booster shots in …
NICE expands guidance for lokelma in adult patients with persistent hyperkalaemia
January 24, 2022Sales and Marketing
NICE have updated the Technology Appraisal Guidance (TAG) for Lokelma (sodium zirconium cyclosilicate SZC) in the treatment of adult patients …
Veklury obtains FDA approval for COVID-19 outpatients
January 24, 2022Sales and Marketing
The FDA has granted expedited approval of a supplemental new drug application (sNDA) for Veklury (remdesivir) for he treatment of …
EU health ministers consider fourth COVID-19 vaccine dose
January 21, 2022Medical Communications
European Union health ministers will try to find a common line on Friday over a potential fourth dose of COVID-19 …
Amid plans to ease COVID restrictions, dialysis patients remain vulnerable to Omicron
January 21, 2022Medical Communications
As the government in England relaxes COVID-19 restrictions, new data from the Francis Crick Institute raise concerns over the impact …
Artificial pancreas may prove life-changing for young children with diabetes
January 21, 2022Medical Communications
Cambridge researchers have developed an artificial pancreas which may beat standard treatment in controlling Type 1 diabetes in young children. …
Clover reveals positive data from Phase II/III COVID-19 vaccine trial
January 21, 2022Medical Communications
Clover Biopharmaceuticals has announced that final efficacy data from SPECTRA, a global Phase II/III clinical trial into its COVID-19 vaccine …
LUMAKRAS (sotorasib) receives approval in Japan for lung cancer patients
January 20, 2022Business Services
Amgen has announced that LUMAKRAS received approval in Japan for the treatment of patients with KRAS G12C-mutated advanced non-small cell …
All Plan B restrictions to end in England
January 20, 2022Business Services
Prime Minister Boris Johnson has announced that England’s Plan B measures are to end from 26 January. This will include …
1.27 million deaths a year attributable to antimicrobial resistance
January 20, 2022Business Services
The Global Research on Antimicrobial Resistance (GRAM) paper has revealed the true scale of antibiotic resistance in Western Europe, and …
Vaccine alliance Gavi says that additional $5.2bn needed to ensure supply
January 20, 2022Business Services
The chairman of the Gavi vaccine alliance, Jose Manuel Barroso, has said that an additional $5.2 billion is required to …
Engitix and Dompé collaboration for fibrosis and cancer AI drug discovery
January 19, 2022Research and Development
Engitix has announced the close of its $54m Series A financing, as well as a strategic collaboration, with Dompé farmaceutici …
MHRA license Jyseleca for treatment of ulcerative colitis
January 19, 2022Research and Development
Galapagos NV, the Belgian parent company of Galapagos Biotech Ltd, have announced that Jyseleca® (filgotinib 200mg tablets) has been granted …
UK launch of generic lenalidomide for myeloma
January 19, 2022Research and Development
Accord Healthcare have announced the UK launch of generic lenalidomide, available for the treatment of adult patients with multiple myeloma, …
SMC accepts first-line treatment for lung cancer
January 19, 2022Research and Development
The SMC has accepted AstraZeneca’s Tagrisso (osimertinib) for use as monotherapy for the first-line treatment of adult patients with locally …
Julie Beeso joins Envision Pharma Group as new Global Director
January 18, 2022Manufacturing and Production
Envision Pharma Group has appointed Julie Beeso as its Global Director, Professional Development and Engagement. Julie has worked for almost …
Mario Torchia appointed as new Vice President of Sales & Marketing at InSilicoTrials
January 18, 2022Manufacturing and Production
InSilicoTrials, a leader in simulation software solutions for healthcare, has announced Mario Torchia’s appointment. Torchia recently led the Sales Strategy …
Enhertu granted priority review in US for patients with HER2-positive metastatic breast cancer
January 18, 2022Manufacturing and Production
Enhertu, manufactured by AstraZeneca and Daiichi Sankyo, has been accepted for the treatment of adult patients in the US with …
SMC accept Enhertu for the treatment of HER2 positive metastatic breast cancer
January 18, 2022Manufacturing and Production
Daiichi Sankyo and AstraZeneca have announced that the SMC has accepted Enhertu® for use within NHS Scotland for the treatment …
Almirall and IRB Barcelona research for skin disease therapeutics discovery
January 18, 2022Manufacturing and Production
Almirall and IRB Barcelona (the Institute for Research in Biomedicine) have announced a research collaboration to identify the new oral …
Latest content
